YMAB Financial Statements From 2010 to 2024

YMAB Stock  USD 11.92  0.04  0.34%   
Y MAbs financial statements provide useful quarterly and yearly information to potential Y mAbs Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Y MAbs financial statements helps investors assess Y MAbs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Y MAbs' valuation are summarized below:
Gross Profit
57.7 M
Profit Margin
(0.28)
Market Capitalization
533.9 M
Enterprise Value Revenue
5.5213
Revenue
84.6 M
We have found one hundred twenty available fundamental gauges for Y mAbs Therapeutics, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of Y mAbs Therapeutics prevalent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself next year. As of December 1, 2024, Market Cap is expected to decline to about 282.8 M. In addition to that, Enterprise Value is expected to decline to about 209.4 M

Y MAbs Total Revenue

89.06 Million

Check Y MAbs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Y MAbs' main balance sheet or income statement drivers, such as Interest Expense of 821.4 K, Selling General Administrative of 33.2 M or Total Revenue of 89.1 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 2.8. YMAB financial statements analysis is a perfect complement when working with Y MAbs Valuation or Volatility modules.
  
Check out the analysis of Y MAbs Correlation against competitors.

Y MAbs Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets150.1 M127.9 M89.7 M
Slightly volatile
Other Current Liabilities7.2 M12.3 M4.3 M
Slightly volatile
Total Current Liabilities17.8 M20.1 M11 M
Slightly volatile
Total Stockholder Equity127.8 M101 M75.3 M
Slightly volatile
Other LiabilitiesM3.5 M2.6 M
Slightly volatile
Net Tangible Assets129.5 M122.2 M76.5 M
Slightly volatile
Accounts PayableM6.1 M5.9 M
Slightly volatile
Cash129.7 M78.6 M78.3 M
Slightly volatile
Cash And Short Term Investments129.7 M78.6 M78.3 M
Slightly volatile
Common Stock Total Equity3.7 K4.6 KK
Slightly volatile
Common Stock Shares Outstanding41.4 M43.6 M36.2 M
Slightly volatile
Short Term Investments33 K36.8 K30.5 K
Slightly volatile
Liabilities And Stockholders Equity150.1 M127.9 M89.7 M
Slightly volatile
Non Current Liabilities Total4.5 M6.8 M3.4 M
Slightly volatile
Capital Surpluse304.2 M597.1 M219.1 M
Slightly volatile
Other Current Assets4.9 MM2.8 M
Slightly volatile
Other Stockholder Equity379.6 M558 M223.2 M
Slightly volatile
Total Liabilities22.3 M26.9 M14.4 M
Slightly volatile
Total Current Assets142.8 M111.1 M85.6 M
Slightly volatile
Common Stock3.9 K4.6 KK
Slightly volatile
Other Assets0.951.015.1 M
Pretty Stable
Deferred Long Term Liabilities617.6 K694.8 K756.6 K
Slightly volatile
Net Invested Capital104.9 M101 M106.5 M
Slightly volatile
Net Working Capital102.2 M91 M105.4 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.6 M1.6 M
Slightly volatile
Property Plant And Equipment Gross1.6 M1.6 M1.6 M
Slightly volatile
Capital Stock4.2 K4.6 K3.5 K
Slightly volatile
Non Current Liabilities Other820.8 K864 K1.1 M
Slightly volatile
Property Plant Equipment3.1 M2.7 M1.4 M
Slightly volatile
Short and Long Term Debt Total2.1 M1.4 M2.3 M
Very volatile
Capital Lease Obligations2.1 M1.4 M2.3 M
Very volatile
Short Term Debt2.5 M1.8 M1.2 M
Slightly volatile
Net Receivables12 M22.5 M4.2 M
Slightly volatile
Intangible Assets2.7 M2.6 M1.9 M
Slightly volatile

Y MAbs Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative33.2 M44.5 M19.6 M
Slightly volatile
Other Operating Expenses99.3 M110.5 M61.6 M
Slightly volatile
Research Development63.1 M54.2 M40.3 M
Slightly volatile
Total Operating Expenses96.3 M99.1 M59.9 M
Slightly volatile
Interest Income979.4 K687.7 K420.7 K
Slightly volatile
Depreciation And Amortization540.3 K735 K248 K
Slightly volatile

Y MAbs Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation11.4 M14.5 M6.4 M
Slightly volatile
Begin Period Cash Flow120.1 M105.8 M69.9 M
Slightly volatile
Total Cash From Financing Activities95 K100 K37.8 M
Very volatile
End Period Cash Flow129.7 M78.6 M78.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.333.509472.2085
Slightly volatile
PTB Ratio2.82.947634.2351
Slightly volatile
Days Sales Outstanding65.9796.625980.0416
Pretty Stable
Book Value Per Share2.52.31381.9775
Slightly volatile
Stock Based Compensation To Revenue0.160.17040.6554
Slightly volatile
Capex To Depreciation1.351.426.0095
Slightly volatile
PB Ratio2.82.947634.2351
Slightly volatile
EV To Sales2.472.59967.7336
Slightly volatile
Payables Turnover1.981.88380.3255
Slightly volatile
Sales General And Administrative To Revenue1.731.942.1152
Slightly volatile
Research And Ddevelopement To Revenue0.610.63923.6663
Slightly volatile
Capex To Revenue0.01450.02490.0125
Slightly volatile
Cash Per Share2.551.80172.075
Slightly volatile
Days Payables Outstanding18419445.9 K
Slightly volatile
Income Quality0.81.27090.8504
Slightly volatile
Intangibles To Total Assets0.01320.02060.0099
Slightly volatile
Current Ratio10.075.52027.8716
Pretty Stable
Tangible Book Value Per Share2.482.25351.965
Slightly volatile
Receivables Turnover4.953.77754.5491
Very volatile
Graham Number7.795.05556.5318
Slightly volatile
Shareholders Equity Per Share2.52.31381.9775
Slightly volatile
Debt To Equity0.00770.00890.0053
Slightly volatile
Capex Per Share0.0250.02580.0153
Slightly volatile
Graham Net Net2.231.62961.7786
Slightly volatile
Revenue Per Share2.041.94340.7983
Slightly volatile
Interest Debt Per Share0.01960.02070.0623
Slightly volatile
Debt To Assets0.00620.00710.0044
Slightly volatile
Price Book Value Ratio2.82.947634.2351
Slightly volatile
Days Of Payables Outstanding18419445.9 K
Slightly volatile
Ebt Per Ebit1.00.81280.9517
Slightly volatile
Company Equity Multiplier0.971.26621.2846
Slightly volatile
Total Debt To Capitalization0.00760.00890.0052
Slightly volatile
Debt Equity Ratio0.00770.00890.0053
Slightly volatile
Quick Ratio9.985.26867.8226
Pretty Stable
Net Income Per E B T0.81.02690.9721
Pretty Stable
Cash Ratio3.713.90687.0875
Very volatile
Days Of Sales Outstanding65.9796.625980.0416
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.161.0246
Slightly volatile
Price To Book Ratio2.82.947634.2351
Slightly volatile
Fixed Asset Turnover54.4451.845411.7315
Slightly volatile
Debt Ratio0.00620.00710.0044
Slightly volatile
Price Sales Ratio3.333.509472.2085
Slightly volatile
Asset Turnover0.70.66330.2478
Slightly volatile
Gross Profit Margin0.980.86540.8993
Slightly volatile
Price Fair Value2.82.947634.2351
Slightly volatile

Y MAbs Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap282.8 M297.7 M715.6 M
Very volatile
Enterprise Value209.4 M220.4 M583.3 M
Very volatile

YMAB Fundamental Market Drivers

Forward Price Earnings119.0476
Cash And Short Term Investments78.6 M

YMAB Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Y MAbs Financial Statements

Y MAbs stakeholders use historical fundamental indicators, such as Y MAbs' revenue or net income, to determine how well the company is positioned to perform in the future. Although Y MAbs investors may analyze each financial statement separately, they are all interrelated. For example, changes in Y MAbs' assets and liabilities are reflected in the revenues and expenses on Y MAbs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Y mAbs Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue84.8 M89.1 M
Cost Of Revenue11.4 M12 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 1.94  1.73 
Research And Ddevelopement To Revenue 0.64  0.61 
Capex To Revenue 0.02  0.01 
Revenue Per Share 1.94  2.04 
Ebit Per Revenue(0.30)(0.32)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:
Check out the analysis of Y MAbs Correlation against competitors.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.54)
Revenue Per Share
1.921
Quarterly Revenue Growth
(0.1)
Return On Assets
(0.12)
Return On Equity
(0.25)
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.